Роль блокаторов ангиогенеза в терапии метастатического рака яичника

Читать PDF

Аннотация

Высокая заболеваемость раком яичника, выявление большинства пациенток в поздних стадиях (65–70% – III–IV стадия), короткий безрецидивный период, неоднократные последующие операции и курсы химиотерапии обусловливают необходимость поиска эффективных режимов терапии. В настоящее время стандартом химиотерапии 1 и 2-й линии распространенного рака яичников является платиносодержащая химиотерапия с добавлением таргетного препарата (бевацизумаб). С целью улучшения результатов выживаемости необходимо дальнейшее изучение использования бевацизумаба в комбинации с химиотерапией в последующих линиях терапии метастатического рака яичника в практике лечебных учреждений Российской Федерации.

Ключевые слова: метастатический рак яичника, химиотерапия, блокада ангиогенеза.

________________________________________________

High incidence of ovarian cancer, the identification of the majority of patients in late stages (65–70% – III–IV stage), short-term survival until relapse, repeated following surgeries and chemotherapy determine the necessity of search for effective treatment regimens. Nowadays platinum-based chemotherapy in addition with targeted therapy (bevacizumab) is standard chemotherapy for first and second line of advanced ovarian cancer. To improve the results of survival, further study of the use of bevacizumab in combination with chemotherapy in the subsequent lines of therapy for metastatic ovarian cancer is necessary.

Key words: metastatic ovarian cancer, chemotherapy, inhibition of angiogenesis.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2010; 21 (Прил. 1).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer 2013.
4. Du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 (8S): viii7–12.
5. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.
6. Du Bois A, Lück H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320–9.
7. Ledermann JA, Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006; 5: 341–54.
8. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21: 149s–167s.
9. Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002; 3: 529–36.
10. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699–708.
11. Sullivan BD, Bicknell R. New molecular pathways in angiogenesis. Br J Cancer 2003; 89: 228–31.
12. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5: 194–204.
13. Hartenbach EM, Olson TA, Goswitz JJ et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997; 23: 169–75.
14. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011; 121: 230–8.
15. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1–7.
16. Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011; 18: 31–43.
17. Presta LG, Chen H, O’Conner SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and the other disorders. Cancer Res 1997; 57: 4593–9.
18. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987–9.
19. Sweeney CJ, Miller KD, Sissons SE et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369–72.
20. Kabbinavar FF, Wong JT, Ayala RE et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res 1995; 36: 488.
21. Kanai T, Konno H, Tanaka T et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77: 933–6.
22. Perren T, Swartz AM, Pfisterer J et al. ICON7: A phase III randomised Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010; 21 (Suppl. 8). Abstr LBA4.
23. Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010; 28 (Suppl.). Abstr. LBA1.
24. Penson RT, Dizon DS, Cannistra SA et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010; 28: 154–9.
25. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165–71.
26. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180–6.
27. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008; 26: 76–82.
28. McGonigle KF, Muntz HG, Vuky J et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer (OV). J Clin Oncol 2008; 26 (15S). Abstr 5551.
29. Micha JP, Goldstein BH, Rettenmaier MA et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17: 771–6.

Авторы

М.Р.Оганян, М.В.Казанцева, И.С.Давиденко, Н.В.Порханова

ГБУЗ Клинический онкологический диспансер №1 Минздрава Краснодарского края

________________________________________________

M.R.Oganian, M.V.Kazantseva, I.S.Davidenko, N.V.Porhanova

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.